Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Add Yahoo as a preferred source to see more of our stories on Google. logos of OpenAI Anadolu via Getty Images There’s interesting news coming from Sam Altman’s empire, a firm known for innovating as ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

So, you want to get better at Python? That’s cool. There are a ton of ways to learn, but honestly, just messing around with code and seeing how things work is a pretty solid approach. This article is ...

Every January, YouTube’s CEO publishes a letter outlining where the platform is headed. In most years, these updates read like a product roadmap. Neal Mohan’s 2026 letter reads more like a strategic ...

It was one Christmas visitor that didn’t overstay its welcome. A Burmese python that had been spotted in a Miami-Dade neighborhood was removed just days before Christmas after a resident out for a ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Got a confidential news tip? We want to hear from you. Sign up ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...